Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway.
Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
JAMA Netw Open. 2022 Dec 1;5(12):e2244495. doi: 10.1001/jamanetworkopen.2022.44495.
Observational studies have reported an association between the use of eye protection and reduced risk of infection with SARS-CoV-2 and other respiratory viruses, but, as with most infection control measures, no randomized clinical trials have been conducted.
To evaluate the effectiveness of wearing glasses in public as protection against being infected with SARS-CoV-2 and other respiratory viruses.
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted in Norway from February 2 to April 24, 2022; all adult members of the public who did not regularly wear glasses, had no symptoms of COVID-19, and did not have COVID-19 in the last 6 weeks were eligible.
Wearing glasses (eg, sunglasses) when close to others in public spaces for 2 weeks.
The primary outcome was a positive COVID-19 test result reported to the Norwegian Surveillance System for Communicable Diseases. Secondary outcomes included a positive COVID-19 test result and respiratory infection based on self-report. All analyses adhered to the intention-to-treat principle.
A total of 3717 adults (2439 women [65.6%]; mean [SD] age, 46.9 [15.1] years) were randomized. All were identified and followed up in the registries, and 3231 (86.9%) responded to the end of study questionnaire. The proportions with a reported positive COVID-19 test result in the national registry were 3.7% (68 of 1852) in the intervention group and 3.5% (65 of 1865) in the control group (absolute risk difference, 0.2%; 95% CI, -1.0% to 1.4%; relative risk, 1.10; 95% CI, 0.75-1.50). The proportions with a positive COVID-19 test result based on self-report were 9.6% (177 of 1852) in the intervention group and 11.5% (214 of 1865) in the control group (absolute risk difference, -1.9%; 95% CI, -3.9% to 0.1%; relative risk, 0.83; 95% CI, 0.69-1.00). The risk of respiratory infections based on self-reported symptoms was lower in the intervention group (30.8% [571 of 1852]) than in the control group (34.1% [636 of 1865]; absolute risk difference, -3.3%; 95% CI, -6.3% to -0.3%; relative risk, 0.90; 95% CI, 0.82-0.99).
In this randomized clinical trial, wearing glasses in the community was not protective regarding the primary outcome of a reported positive COVID-19 test. However, results were limited by a small sample size and other issues. Glasses may be worth considering as one component in infection control, pending further studies.
ClinicalTrials.gov Identifier: NCT05217797.
观察性研究报告表明，使用眼部防护设备与降低 SARS-CoV-2 和其他呼吸道病毒感染风险之间存在关联，但与大多数感染控制措施一样，尚未进行随机临床试验。
评估在公共场所戴眼镜作为预防感染 SARS-CoV-2 和其他呼吸道病毒的有效性。
设计、地点和参与者：2022 年 2 月 2 日至 4 月 24 日，在挪威进行了一项随机临床试验；所有未定期戴眼镜、无 COVID-19 症状且过去 6 周内未感染 COVID-19 的成年公众均可参加。
在公共场所与他人近距离接触时佩戴眼镜（例如太阳镜）两周。
主要结局是向挪威传染病监测系统报告的 COVID-19 阳性检测结果。次要结局包括基于自我报告的 COVID-19 阳性检测结果和呼吸道感染。所有分析均遵循意向治疗原则。
共有 3717 名成年人（2439 名女性[65.6%]；平均[标准差]年龄 46.9[15.1]岁）被随机分组。所有人均在登记处被识别并进行随访，3231 人（86.9%）对研究结束时的问卷做出了回应。在国家登记处报告 COVID-19 阳性检测结果的比例分别为干预组 3.7%（68/1852）和对照组 3.5%（65/1865）（绝对风险差异，0.2%；95%CI，-1.0%至 1.4%；相对风险，1.10；95%CI，0.75-1.50）。基于自我报告 COVID-19 阳性检测结果的比例分别为干预组 9.6%（177/1852）和对照组 11.5%（214/1865）（绝对风险差异，-1.9%；95%CI，-3.9%至 0.1%；相对风险，0.83；95%CI，0.69-1.00）。基于自我报告的症状，干预组呼吸道感染的风险（30.8%[1852 例中的 571 例]）低于对照组（34.1%[1865 例中的 636 例]）（绝对风险差异，-3.3%；95%CI，-6.3%至-0.3%；相对风险，0.90；95%CI，0.82-0.99）。
在这项随机临床试验中，在社区中戴眼镜对于报告 COVID-19 阳性检测结果的主要结局没有保护作用。然而，结果受到样本量小和其他问题的限制。在等待进一步研究的情况下，眼镜可能值得考虑作为感染控制的一个组成部分。
ClinicalTrials.gov 标识符：NCT05217797。
